Genecast Trio Focus - Genecast Group Inc.

Genecast Trio Focus

Product Detais

Resources

How it works

Genecast Trio Focus is a molecular diagnostic product for guiding medication for patients with 3 main types of solid tumors, including lung cancer, colorectal cancer and breast cancer. It is a hybrid capture based targeted sequencing assay designed to evaluate somatic variants across multiple driver genes from blood samples. It provides comprehensive mutation data crucial for assessing sensitivity to targeted drugs and prognostic factors, including SNV, Indel, CNV, and fusion/rearrangement.

Specifications

Enrichment Method	Hybrid capture
Panel Design	29 genes
Sequencing Platforms	DNBSEQ-G400/NextSeq 550
Package	48 tests/kit
Catalog Number	ZYCE-00101

Applications

Genecast Trio Focus analyzes ctDNA from patient's blood to detect cancer-related gene mutations. It is a non-invasive liquid biopsy option, particularly useful when tumor tissue is unavailable, or difficult to obtain.

Molecular profiling & targeted therapy selection

Detects actionable mutations (e.g., EGFR, ALK, KRAS, BRAF) to guide treatment decisions, especially when tissue biopsy is not feasible or a rapid result is needed.

Resistance monitoring & treatment switching

Identifies resistance mutations (e.g., EGFR T790M) upon disease progression, supporting decisions on subsequent therapy.

Sample Specifications

Type	Requirements
Blood Sample	≥ 8mL, 1 tube, cfDNA BCT.

In Summary

Requires only a blood sample; no tumor tissue is needed.

Targets treatment-relevant genes, directly supporting clinical decisions.

Reliable detection of low-frequency mutations in plasma.

Compatible with MGI and Illumina sequencing platforms.